San Francisco, CA USA
October 10-11, 2018

JOIN MAILING LIST BROCHURE SPEAKING OPPS

Privacy Policy

Effective date: May 21, 2018

Arrowhead Publishers LLC ("us", "we", or "our") operates the http://www.paintherapeuticsummit.com website (the "Service").

This page informs you of our policies regarding the collection, use, and disclosure of personal data when you use our Service and the choices you have associated with that data.

We use your data to provide and improve the Service. By using the Service, you agree to the collection and use of information in accordance with this policy. Unless otherwise defined in this Privacy Policy, terms used in this Privacy Policy have the same meanings as in our Terms and Conditions, accessible from http://www.paintherapeuticsummit.com

Definitions

  • Service

    Service is the http://www.paintherapeuticsummit.com website operated by Arrowhead Publishers LLC

  • Personal Data

    Personal Data means data about a living individual who can be identified from those data (or from those and other information either in our possession or likely to come into our possession).

  • Usage Data

    Usage Data is data collected automatically either generated by the use of the Service or from the Service infrastructure itself (for example, the duration of a page visit).

  • Cookies

    Cookies are small pieces of data stored on your device (computer or mobile device).

  • Data Controller

    Data Controller means the natural or legal person who (either alone or jointly or in common with other persons) determines the purposes for which and the manner in which any personal information are, or are to be, processed.

    For the purpose of this Privacy Policy, we are a Data Controller of your Personal Data.

  • Data Processors (or Service Providers)

    Data Processor (or Service Provider) means any natural or legal person who processes the data on behalf of the Data Controller.

    We may use the services of various Service Providers in order to process your data more effectively.

  • Data Subject (or User)

    Data Subject is any living individual who is using our Service and is the subject of Personal Data.

Information Collection And Use

We collect several different types of information for various purposes to provide and improve our Service to you.

Types of Data Collected

Personal Data

While using our Service, we may ask you to provide us with certain personally identifiable information that can be used to contact or identify you ("Personal Data"). Personally identifiable information may include, but is not limited to:

  • Email address
  • First name and last name
  • Phone number
  • Cookies and Usage Data

We may use your Personal Data to contact you with newsletters, marketing or promotional materials and other information that may be of interest to you. You may opt out of receiving any, or all, of these communications from us by following the unsubscribe link or instructions provided in any email we send or by contacting us.

Usage Data

We may also collect information how the Service is accessed and used ("Usage Data"). This Usage Data may include information such as your computer's Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Service that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.

Tracking & Cookies Data

We use cookies and similar tracking technologies to track the activity on our Service and hold certain information.

Cookies are files with small amount of data which may include an anonymous unique identifier. Cookies are sent to your browser from a website and stored on your device. Tracking technologies also used are beacons, tags, and scripts to collect and track information and to improve and analyze our Service.

You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our Service.

Examples of Cookies we use:

  • Session Cookies. We use Session Cookies to operate our Service.
  • Preference Cookies. We use Preference Cookies to remember your preferences and various settings.
  • Security Cookies. We use Security Cookies for security purposes.

Use of Data

Arrowhead Publishers LLC uses the collected data for various purposes:

  • To provide and maintain our Service
  • To notify you about changes to our Service
  • To allow you to participate in interactive features of our Service when you choose to do so
  • To provide customer support
  • To gather analysis or valuable information so that we can improve our Service
  • To monitor the usage of our Service
  • To detect, prevent and address technical issues
  • To provide you with news, special offers and general information about other goods, services and events which we offer that are similar to those that you have already purchased or enquired about unless you have opted not to receive such information

Legal Basis for Processing Personal Data Under General Data Protection Regulation (GDPR)

If you are from the European Economic Area (EEA), Arrowhead Publishers LLC legal basis for collecting and using the personal information described in this Privacy Policy depends on the Personal Data we collect and the specific context in which we collect it.

Arrowhead Publishers LLC may process your Personal Data because:

  • We need to perform a contract with you
  • You have given us permission to do so
  • The processing is in our legitimate interests and it's not overridden by your rights
  • For payment processing purposes
  • To comply with the law

Retention of Data

Arrowhead Publishers LLC will retain your Personal Data only for as long as is necessary for the purposes set out in this Privacy Policy. We will retain and use your Personal Data to the extent necessary to comply with our legal obligations (for example, if we are required to retain your data to comply with applicable laws), resolve disputes, and enforce our legal agreements and policies.

Arrowhead Publishers LLC will also retain Usage Data for internal analysis purposes. Usage Data is generally retained for a shorter period of time, except when this data is used to strengthen the security or to improve the functionality of our Service, or we are legally obligated to retain this data for longer time periods.

Transfer Of Data

Your information, including Personal Data, may be transferred to — and maintained on — computers located outside of your state, province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.

If you are located outside United States and choose to provide information to us, please note that we transfer the data, including Personal Data, to United States and process it there.

Your consent to this Privacy Policy followed by your submission of such information represents your agreement to that transfer.

Arrowhead Publishers LLC will take all steps reasonably necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your Personal Data will take place to an organization or a country unless there are adequate controls in place including the security of your data and other personal information.

Disclosure Of Data

Business Transaction

If Arrowhead Publishers LLC is involved in a merger, acquisition or asset sale, your Personal Data may be transferred. We will provide notice before your Personal Data is transferred and becomes subject to a different Privacy Policy.

Disclosure for Law Enforcement

Under certain circumstances, Arrowhead Publishers LLC may be required to disclose your Personal Data if required to do so by law or in response to valid requests by public authorities (e.g. a court or a government agency).

Legal Requirements

Arrowhead Publishers LLC may disclose your Personal Data in the good faith belief that such action is necessary to:

  • To comply with a legal obligation
  • To protect and defend the rights or property of Arrowhead Publishers LLC
  • To prevent or investigate possible wrongdoing in connection with the Service
  • To protect the personal safety of users of the Service or the public
  • To protect against legal liability

Security Of Data

The security of your data is important to us, but remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. While we strive to use commercially acceptable means to protect your Personal Data, we cannot guarantee its absolute security.

"Do Not Track" Signals

We do not support Do Not Track ("DNT"). Do Not Track is a preference you can set in your web browser to inform websites that you do not want to be tracked.

You can enable or disable Do Not Track by visiting the Preferences or Settings page of your web browser.

Your Data Protection Rights Under General Data Protection Regulation (GDPR)

If you are a resident of the European Economic Area (EEA), you have certain data protection rights. Arrowhead Publishers LLC aims to take reasonable steps to allow you to correct, amend, delete, or limit the use of your Personal Data.

If you wish to be informed what Personal Data we hold about you and if you want it to be removed from our systems, please contact us.

In certain circumstances, you have the following data protection rights:

  • The right to access, update or to delete the information we have on you. Whenever made possible, you can access, update or request deletion of your Personal Data directly within your account settings section. If you are unable to perform these actions yourself, please contact us to assist you.

  • The right of rectification. You have the right to have your information rectified if that information is inaccurate or incomplete.

  • The right to object. You have the right to object to our processing of your Personal Data.

  • The right of restriction. You have the right to request that we restrict the processing of your personal information.

  • The right to data portability. You have the right to be provided with a copy of the information we have on you in a structured, machine-readable and commonly used format.

  • The right to withdraw consent. You also have the right to withdraw your consent at any time where Arrowhead Publishers LLC relied on your consent to process your personal information.

Please note that we may ask you to verify your identity before responding to such requests.

You have the right to complain to a Data Protection Authority about our collection and use of your Personal Data. For more information, please contact your local data protection authority in the European Economic Area (EEA).

Service Providers

We may employ third party companies and individuals to facilitate our Service ("Service Providers"), to provide the Service on our behalf, to perform Service-related services or to assist us in analyzing how our Service is used.

These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.

Analytics

We may use third-party Service Providers to monitor and analyze the use of our Service.

  • Google Analytics

    Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our Service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.

    You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.

    For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page: http://www.google.com/intl/en/policies/privacy/

Behavioral Remarketing

Arrowhead Publishers LLC uses remarketing services to advertise on third party websites to you after you visited our Service. We and our third-party vendors use cookies to inform, optimize and serve ads based on your past visits to our Service.

  • Google AdWords

    Google AdWords remarketing service is provided by Google Inc.

    You can opt-out of Google Analytics for Display Advertising and customize the Google Display Network ads by visiting the Google Ads Settings page: http://www.google.com/settings/ads

    Google also recommends installing the Google Analytics Opt-out Browser Add-on - https://tools.google.com/dlpage/gaoptout - for your web browser. Google Analytics Opt-out Browser Add-on provides visitors with the ability to prevent their data from being collected and used by Google Analytics.

    For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page: http://www.google.com/intl/en/policies/privacy/

Payments

We may provide paid products and/or services within the Service. In that case, we use third-party services for payment processing (e.g. payment processors).

We will not store or collect your payment card details. That information is provided directly to our third-party payment processors whose use of your personal information is governed by their Privacy Policy. These payment processors adhere to the standards set by PCI-DSS as managed by the PCI Security Standards Council, which is a joint effort of brands like Visa, Mastercard, American Express and Discover. PCI-DSS requirements help ensure the secure handling of payment information.

The payment processors we work with are:

Links To Other Sites

Our Service may contain links to other sites that are not operated by us. If you click on a third party link, you will be directed to that third party's site. We strongly advise you to review the Privacy Policy of every site you visit.

We have no control over and assume no responsibility for the content, privacy policies or practices of any third party sites or services.

Children's Privacy

Our Service does not address anyone under the age of 18 ("Children").

We do not knowingly collect personally identifiable information from anyone under the age of 18. If you are a parent or guardian and you are aware that your Children has provided us with Personal Data, please contact us. If we become aware that we have collected Personal Data from children without verification of parental consent, we take steps to remove that information from our servers.

Changes To This Privacy Policy

We may update our Privacy Policy from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.

We will let you know via email and/or a prominent notice on our Service, prior to the change becoming effective and update the "effective date" at the top of this Privacy Policy.

You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.

Contact Us

If you have any questions about this Privacy Policy, please contact us:

  • By email: This email address is being protected from spambots. You need JavaScript enabled to view it.
  • By phone number: 966-945-0263
  • By mail: PO Box 96, Chanhassen, MN 55317

About Us

Arrowhead Publishers' conferences offer more than simply presentations; we offer an experience that encompasses learning, networking and professional growth. We focus on bringing life sciences industry professionals together to help move research forward. 
READ MORE

Contact Us

For general information about the conference, please contact us at:
 This email address is being protected from spambots. You need JavaScript enabled to view it.
 +866.945.0263
 +866.945.0263
  PO Box 96, Chanhassen, MN 55317 USA

PRIVACY POLICY

Join Our Mailing List
 
Please fill out the following form in order to receive occasional updates regarding this conference, including updates regarding the agenda, speaker additions and conference promotions and DISCOUNTS.
 
We never share your personal data with anyone else, EVER!
 
 
 
 
Michael G. Palfreyman, Ph.D., DSc.

Chief Scientific Officer, Amorsa Therapeutics

Michael Palfreyman is a seasoned leader in the biotechnology and pharmaceutical industries with over 40 years experience in drug discovery, pre-clinical and early clinical development. He has directed research programs in Psychiatric, Neurological, Cardiovascular, Cancer, Infectious, Metabolic and Respiratory Disorders, Dr. Palfreyman’s own research includes discovery and development of a number of psychotherapeutic compounds including antipsychotics, antidepressants, anti-epileptics, analgesics, anti-Parkinson’s, anti-emetics, cognition enhancers and Alzheimer’s treatments. Many of these compounds have entered clinical development and a number have reached the market place. 

He is a Fellow of the American College of NeuroPsychopharmacology and he is a qualified Pharmacist and Founding Member Royal Pharmaceutical Society of Great Britain. He is the co-inventor of 53 issued US and European patents, 4 pending patents and co-author of over 100 peer reviewed scientific articles, has edited books on glutamate antagonists and enzyme inhibitors and authored several book chapters on a number of different therapeutics. He is currently Chief Scientific Officer at Amorsa Therapeutics.

Nathaniel Katz, MD, MS

Chief Executive Officer, Analgesic Solutions
Dr. Nathaniel Katz is considered one of the leading experts of treatment and clinical study design in pain clinical trials. He is a neurologist and pain management specialist with a distinguished career at Harvard Medical School, Brigham & Women’s Hospital and Dana Farber Cancer Institute. From 2000-2004 he served as Chair of the Advisory Committee, Anesthesia, Critical Care, and Addiction Products Division, United States FDA, during which time he completed a Master of Science in Biostatistics at Columbia University.

Dr. Katz’s holds the position of Adjunct Assistant Professor of Anesthesia at Tufts School of Medicine. He has completed numerous clinical trials of treatments for pain, both industry-initiated and investigator-initiated, involving pharmaceuticals, non-pharmaceutical analgesics and devices, and has also conducted studies related to opioids, pain, addiction, and other issues related to opioid therapy. Dr. Katz was an Associate Editor at the Clinical Journal of Pain, and Associate Editor (Pain) for the Encyclopedia of Neurological Sciences.

Philippe Diaz, Ph.D.

Associate Professor, University of Montana, Co-Founder and Chief Scientific Officer, DermaXon
Dr. Diaz has more than 20 years of experience leading small and large teams of research scientists within both academics and industry. He started his career in Galderma R&D where he held senior leadership roles in the in the drug discovery department. He was senior scientist at Department of Anesthesiology and Pain Medicine at MD Anderson Cancer Center in Houston where he became interested by the complexity of cannabinoid pharmacology and the design of small molecules to treat Pain.

Philippe holds a Ph.D. in chemistry from the University of Aix-Marseille and an engineering degree in Chemistry from ENSSPICAM (now Ecole Centrale de Marseille). He has authored more than 30 peer-reviewed publications and is co-inventor of more than 24 patents.

Neil Singla, MD

Chief Scientific Officer, Lotus Clinical Research
Dr. Neil Singla, a board-certified anesthesiologist, is the founder and Chief Scientific Officer of Lotus Clinical Research. Since its inception in 2001, Dr. Singla has served in several roles within the organization including: Research Coordinator, Sub-Investigator, Principal Investigator, Coordinating Investigator, and Chief Scientific Officer.

In his capacity as CSO for Lotus Clinical Research, Dr. Singla has had the opportunity to interact frequently with the FDA’s Analgesics Division on behalf of clients and to play a significant role in guiding development strategies for dozens of putative analgesic agents. In the company’s 17-year history, Dr. Singla and Lotus Clinical Research have played a significant role in bringing several molecules to market.

Dr. Singla has published extensively and is a frequent lecturer for physicians, pharmaceutical companies, and medical research institutes throughout the country. He currently chairs the Analgesic Clinical Trials Shared/Special Interest Group at both the American Pain Society (APS) and the International Association for the Study of Pain (IASP). He chairs the annual APS Conference on Analgesic Clinical Trials (APS-CAT), which aims to help experts advance best practices in analgesic drug development.

The main focus of Dr. Singla’s academic endeavors has been to analyze and understand how the inherent variability in subjective endpoint analgesic clinical trials can be minimized. As a result, he has developed novel techniques for patient education designed to minimize variability, reduce placebo response, and increase effect size.

David Yeomans, Ph.D.

Director of Pain Research, Professor of Anesthesia, Stanford University School of Medicine
David Yeomans is the director of pain research and a professor of anesthesia at Stanford University School of Medicine. His research focuses on elaborating pain mechanisms and exploring novel approaches to the treatment of pain, including targeted transcranial magnetic stimulation and gene therapy. Dr. Yeomans has authored more than 100 articles and 11 book chapters in the field of pain, and has been the recipient of numerous grants and awards from the National Institutes of Health and other granting agencies. He has also been named Pfizer Professor of Pain Medicine and has received multiple visiting professorships.

Dr. Yeomans has authored numerous issued patents and co-founded two companies (Trigemina and SiteOne) devoted to the management of pain. He is the chair of the scientific advisory board of four companies and an advisor to numerous pharmaceutical and biotech companies, as well as venture capital firms and intellectual property law practices. Dr. Yeomans earned an AB degree from Dartmouth College, received his PhD in neuroscience from the University of Florida, and completed his research training as a NIH fellow at the University of Illinois.

Robert H. Dworkin, Ph.D.

Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry, Director, Anesthesiology Research Center, Director, Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION), a public-private partnership with the FDA, University of Rochester School of Medicine and Dentistry
Robert H. Dworkin received his BA from the University of Pennsylvania and his PhD from Harvard University. He is Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry, Professor in the Center for Health + Technology, and Director of the Anesthesiology Clinical Research Center at the University of Rochester School of Medicine and Dentistry.

Dr. Dworkin is Director of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the U.S. Food and Drug Administration (FDA) and a Special Government Employee of the FDA Center for Drug Evaluation and Research; he previously served as a consultant to and member of the FDA Anesthetic and Life Support Drugs Advisory Committee and as a member of the U.S. Centers for Disease Control and Prevention Herpes Zoster Working Group. He is an Associate Editor of Pain, and a member of the Editorial Boards of Journal of Pain, Canadian Journal of Pain, and Current Pain and Headache Reports. Dr. Dworkin received the American Pain Society’s Wilbert E. Fordyce Clinical Investigator Award in 2005 and John and Emma Bonica Public Service Award in 2014, the Eastern Pain Association’s John J. Bonica Award in 2011 and Raymond Houde Lectureship Award in 2018, the American Academy of Neurology’s Mitchell B. Max Award for Neuropathic Pain in 2015, and the American Academy of Pain Medicine’s Founders Award in 2018.

Dr. Dworkin’s major research interests are (1) methodologic aspects of analgesic clinical trials and (2) treatment and prevention of chronic and acute neuropathic and musculoskeletal pain. The primary focus of his current research involves the identification of factors that increase the assay sensitivity of clinical trials to detect differences between an active and a control or comparison treatment. Dr. Dworkin has also been very interested in the identification of risk factors for the transition from acute to chronic pain. One of the major results of this program of research has been that patients with greater acute pain are more likely to develop chronic pain. This suggests that attenuating acute pain might prevent chronic pain, and an additional focus of his research has involved developing approaches to test this hypothesis.

Dr. Dworkin has authored over 300 journal articles and book chapters, which have been cited over 32,000 times (h index = 85). He has served as a consultant to over 150 pharmaceutical and device companies in the development and evaluation of analgesic and antiviral treatments, and as Director of the Anesthesiology Clinical Research Center, has been the principal investigator for a large number of clinical trials funded by government and industry. These studies have examined treatments for various types of chronic pain—including neuropathic pain conditions, low back pain, cancer pain, fibromyalgia, and osteoarthritis—as well as treatments for acute pain in herpes zoster and acute post-surgical pain.

Simon Westbrook, Ph.D.

CEO and Founder, Levicept
Dr. Westbrook a seasoned drug discoverer, the inventor of numerous patents who worked at Pfizer, Sandwich for c. 18 years in a variety of roles and departments including Urology, Cardiovascular/Metabolic Disease and Pain. Whilst in the Pain therapeutic area, Simon worked on the anti-NGF program with the role of identifying novel means of manipulating the neurotrophin pathway.

In September 2012 Simon founded Levicept, a Pfizer-spun out company, with the goal of developing a novel and safe neurotrophin modulator for the treatment of chronic pain.

Mike Royal, MD, JD, MBA

Chief Medical Officer, Concentric Analgesics
Dr. Mike Royal is the Chief Medical Officer of Concentric Analgesics, Inc. (San Francisco). He has 17 years of pain drug development and medical affairs experience particularly in 505(b)(2) NDAs across several indications, but also with NCEs and generics. He has held senior clinical roles at Liquidia Technologies, Sorrento Therapeutics, AcelRx Pharmaceuticals, Cadence Pharmaceuticals, Solstice Neuroscience, Alpharma and Elan Biopharmaceuticals.

Dr. Royal holds Board certifications in Internal Medicine, Anesthesiology, Addiction Medicine and Pain Medicine with 12 years of medical practice experience in both academic and private practice settings. He has over 185 peer-reviewed publications, book chapters, and abstracts/posters. Dr. Royal received a BS in synthetic organic chemistry from MIT, MD from University of Massachusetts, JD from University of Maryland and MBA from TRIUM (NYU Stern School, London School of Economics, HEC-Paris).

Tony Yaksh, Ph.D.

Professor, Departments of Anesthesiology and Pharmacology, University of California, San Diego
Dr. Tony L. Yaksh obtained his Ph.D. degree from Purdue University (1971).He served in the U.S. Army in the Biomedical Laboratory at Edgewood Arsenal, MD (1971-73), was a research scientist in the School of Pharmacy, University of Wisconsin (1973-76) and an Associate Research Scientist in Anatomy at University College London with Pat Wall (1976-77). He worked at the Mayo Clinic with Dr. Frederick Kerr in Rochester, MN in Pharmacology and Neurosurgery (1977-1988), where he rose to the rank of Consultant and Professor.

Dr. Yaksh joined UCSD in 1988 as Professor in the Department of Anesthesiology, and Professor in the Department of Pharmacology and Vice Chairman for Research in Anesthesiology through 2014. His research has been on the biology of pain processing. His studies have provided a basis for understanding the pharmacology of the spinal gating of pain information.

He is an expert in spinal drug kinetics and evaluation of spinal drug safety. He has published 800+ papers and edited 6 texts. His work has garnered over 48,000 citations in over 27,000 papers. He has mentored more than 150 postdoctoral fellows and trainees. He has been funded consistently by NIH since 1977 and twice has been a Javitz Award recipient. He has received numerous awards, including from the American Pain Society (Kerr Award), the International Association for the Study of Pain (Bonica Award) and the Swedish Society of Medicine (Gordh Award).

Alex Bekker, MD, Ph.D.

Chair, Department of Anesthesiology, Professor, Department of Physiology and Pharmacology, Rutgers New Jersey Medical School
Dr. Alex Bekker is Professor and Chairman of Anesthesiology at Rutgers New Jersey Medical School. Dr. Bekker has been active in research and for many years. He is an author of 90+ peer-reviewed articles including publications in Anesthesiology, Pain, Nature Neuroscience, Molecular Pain, and Anesthesia & Analgesia, 6 US patents, 40 + educational reviews and more than 100 abstracts. His work has focused on the effects of anesthetics on CNS, neuroinflammation, neuropathic pain and postoperative analgesia. Dr. Bekker was a PI of numerous clinical trials, including studies sponsored by the National Institute of Health.

Tad Seifert, MD

Director, Sports Neurology Program, Norton Healthcare, Head, NCAA Headache Task Force
Dr. Tad Seifert a graduate of the University of Oklahoma College of Medicine in Oklahoma City, Oklahoma. He completed his residency in neurology at the University of Texas-Houston and a subsequent fellowship in headache & facial pain at the renowned Houston Headache Clinic. Dr. Seifert currently serves as Director of Norton Healthcare’s Sports Neurology Program in Louisville, Kentucky.

Dr. Seifert is an Independent Neurotrauma Consultant for the NFL and serves as Head of the NCAA’s Headache Task Force. He is currently the Team Neurologist for a number of Kentucky and Indiana-based colleges and universities and is Chairman of the Kentucky Boxing & Wrestling Commission’s Medical Advisory Panel. His research interests include post-traumatic headache in athletes as well as combat sports medicine.

Srdjan Nedeljkovic, MD

Associate Professor, Anesthesia and Pain Management, Harvard Medical School, Brigham and Women's Hospital
Dr. Nedeljkovic is anesthesiologist and pain medicine specialist based at Brigham and Women’s Hospital and an Associate Professor of Anaesthesia at Harvard Medical School in Boston, Massachusetts. He is also staff physician in the Spine Unit at Harvard Vanguard Medical Associates in Boston, a large multispecialty physician practice group. Dr. Nedeljkovic has had an extensive experience in pain medicine education, serving as Fellowship Director in Pain Medicine at BWH and as Vice Chair of the Pain Medicine examination committee at the American Board of Anesthesiology. Dr. Nedeljkovic is also a lecturer and course director in the Tufts University School of Public Health's PREP (pain research, education, and policy) program.

Dr. Nedeljkovic has had extensive experience as a leader in clinical pain research, serving as the site Principal Investigator of the BOLD (Back Pain Longitudinal Data) project as well as the LESS (Lumbar Epidural Steroid Injections for Spinal Stenosis) study. Over the past several years, he has led a number of innovative clinical research protocols, including a study of VVZ-149, a novel glycine T2 inhibitor and 5HT2A receptor antagonist. In addition, Dr. Nedeljkovic has served as principal investigator in studies using Exparel, a long-acting liposomal bupivacaine local anesthetic, and a study using RTX (resiniferitoxin), a TRPV1 receptor agonist that causes selective neurolysis of primary sensory neurons responsible for pain perception. Dr. Nedeljkovic is currently in the process of initiating studies on the clinical efficacy of pharmacogenomic testing in the perioperative period and in a pain management center environment.

Shafaq Sikandar, Ph.D.

Research Fellow, University College London
Dr Shafaq Sikandar has more than 10 years of research experience and extensive expertise in using electrophysiology, behaviour, molecular biology and pharmacological assays to study pain in rodents and humans. During her Ph.D. in Pharmacology in University College London, she established new electrophysiological assays for evaluating visceral pain and descending modulation in rodents. In her following first postdoctoral post at University College London, she employed translational approaches to assess pain in rodents and humans in parallel. Her findings showed strong correlations between both species for measures of nociception, thereby substantiating the use of preclinical tests to predict clinical outcomes. These were novel reports of the correlation between evoked neuronal activity in rodent preparations and human perceptual responses to pain.

She was awarded a fellowship to work at UC San Diego, where she studied analgesic mechanisms of botulinum toxin. Her next postdoc was in a molecular genetics lab at the Wolfson Institute of Biomedical Research in University College London, where she has been working on hyperalgesic priming models to study pain plasticity in the nervous system. She is currently an Arthritis Research UK fellow as part of the Centre for Adolescent Rheumatology in London, and continues to use rodent models to identify which subpopulations of sensory neurons mediate the transition of acute to chronic pain.

Joseph F. Foss, MD

Founder, Neurotherapia
Dr. Foss received his undergraduate and medical degrees from Brown University, and his training in clinical pharmacology at the University of Chicago. There he led the development of methylnaltrexone, a peripherally active opioid antagonist. This involved the proof of principle trials in pre-clinical models, the first-in-man studies, and subsequent proof of concept trials and studies of the pharmacokinetics and pharmacodynamics in man. Methylnaltrexone was licensed out and approved for clinical use (as Relistor®) in the management of opioid side effects in patients with advanced medical illness.

Subsequently Dr. Foss worked for Adolor, a small biotech company, which was developing alvimopan, another peripherally acting opioid antagonist, which also has been approved for clinical use. Dr. Foss was also responsible for the translational program there that was developing novel analgesics. Dr. Foss was recruited to the Cleveland Clinic to assist in developing the research program in anesthesiology. Dr. Foss began to work with Dr. Mohamed Naguib recently to provide direct support to the development program for the CB2 agonists. They have done extensive research on the mechanisms by which microglial mediated neuroinflammation plays a role in disease and are currently advancing NTRX-07 into human trials for the treatment of neuropathic pain and Alzheimer’s disease. He is a founder of NeuroTherapia Inc.

Sean Mackey, MD, Ph.D.

Chief, Division of Pain Medicine, Director, Stanford Systems Neuroscience and Pain Lab, Stanford University School of Medicine
Sean Mackey, MD, PhD, is Redlich Professor and Chief of the Stanford Division of Pain Medicine. He uses research tools such as big data, psychophysical, neurobehavioral and neuroimaging tools to investigate chronic pain and opioids. Dr. Mackey is author of over 200 journal articles and book chapters. He is developer of an open-source learning health system—CHOIR (http://choir.stanford.edu)—to transform the care of people with pain, and serve as a platform for research in real-world clinic patients. Recently, he was Co-Chair of the HHS/NIH National Pain Strategy (NPS) to establish a national health strategy for pain care, education and research.


Under Dr. Mackey’s leadership, the Stanford Pain Management Center has been twice designated a Center of Excellence by the American Pain Society for the Center’s innovative approach in comprehensive, interdisciplinary, and outcomes-based care. He has served as principle investigator on multiple NIH awards where he has overseen efforts to map the specific regions of the brain and spinal cord that perceive and process pain.

Robert Cowan, MD, FAAN

Clinical Professor, Neurology and Neurological Sciences, Stanford University School of Medicine
Dr. Robert Cowan is Professor of Neurology and Director of the Headache and Facial Pain Program at Stanford University. He is board certified in neurology and pain medicine with a subspecialty certification in headache medicine. Dr. Cowan holds several nationally elected positions, including chair of the section on chronic daily headache for the American Headache Society.

He is President of the Headache Cooperative of the Pacific, a fellow of the American Academy of Neurology and the American Headache Society. He sits on the board of the Alliance for Headache Diseases Advocacy and the American Headache and Migraine Association. He has published over 50 articles and is the author of The Keeler Migraine Method.

Xinmin Simon Xie, MD, Ph.D.
Founder and Chief Executive Officer, AlfaSci Research Labs
Dr. Xie received his M.D. from the University of Bern, Switzerland, and Ph.D. in Pharmacology from the University of London, U.K. He is the founder and Chief Scientific Officer of AfaSci, Inc., a San Francisco Bay Area based biotech company and leads a team in CNS drug discovery, especially in the therapeutic area of neuropathic pain. Prior to founding AfaSci, he was a Principal Investigator on several NIH Roadmap grants in SRI International, where he established the SRI’s high-throughput screening (HTS) laboratory equipped with FLIPR and patch clamp recording techniques (2003–2008).
 
Previously Dr. Xie was a Research Scientist and then Group Leader of Electrophysiology, at GlaxoWellcome, U.K. He made significant contributions to the discovery of multiple new ion channel modulatory drugs, including lamotrigine (Lamictal®, for epilepsy and bipolar disorder); 4030W92 (for neuropathic pain, Phase II); sipatrigine (i.e., 619C89 for strokes, Phase II); elpetrigine (for epilepsy and bipolar disorder, phase I); and BW534U87 (for refectory epilepsy, Phase I). Dr. Xie has been leading the team in discovery and development of two therapeutic candidates with backup compounds for the treatment of neuropathic pain and neuroinflammatory pain. Both analgesic candidates are non-opioid, non-addictive and non-NSAID analgesics.